The translational potential of ADAMTS4 as a therapeutic target is supported by the findings of the beneficial effects of ADAMTS4 inhibition in rat hearts following pressure overload and that substantially increased ADAMTS4 activity is observed in human heart failure. This evidence concerns the gene ADAMTS4 and heart failure.